Assessing the Impact of Morphine on Adverse Outcomes in ACS Patients Treated with P2Y12 Inhibitors: Insights from Multiple Real-World Evidence
Chenxi Ouyang,Changjiang Meng,Fei Li,Shanshan Nie,Liying Gong,Yu Cao,Hong Yuan,Zeying Feng
DOI: https://doi.org/10.2147/dddt.s458299
IF: 4.3188
2024-05-28
Drug Design Development and Therapy
Abstract:Chenxi Ouyang, 1, 2 Changjiang Meng, 3 Fei Li, 3 Shanshan Nie, 3 Liying Gong, 4 Yu Cao, 5 Hong Yuan, 3, 5 Zeying Feng 6 1 School of Pharmacology, University of South China, Hengyang, Hunan, People's Republic of China; 2 The Affiliated Nanhua Hospital, Department of Pharmacy, Hengyang Medical School University of South China, Hengyang, Hunan, People's Republic of China; 3 Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China; 4 Department of Critical Care Medicine, The Third Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China; 5 Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China; 6 Clinical Trial Institution Office, Liuzhou Hospital of Guangzhou Women and Children's Medical Center, Liuzhou, Guangxi, People's Republic of China Correspondence: Zeying Feng, Clinical Trial Institution Office, Liuzhou Hospital of Guangzhou Women and Children's Medical Center, No. 50 Boyuan Avenue, Liuzhou, Guangxi, 545000, People's Republic of China, Email Purpose: Mechanistic studies showed that morphine may impair the antiplatelet effect of P2Y12 inhibitors. However, Several clinical studies with cardiovascular events as an outcome are contradictory, and the broader impact of this drug interaction on additional organ systems remains uncertain. With multisource data, this study sought to determine the effects of morphine interaction with P2Y12 inhibitors on major adverse outcomes comprehensively, and identify the warning indicators. Patients and Methods: Interaction signals were sought in 187,919 safety reports from the FDA Adverse Event Reporting System (FAERS) database, utilizing reporting odds ratios (repOR). In a cohort of 5240 acute coronary syndrome patients, the analyses were validated, and the biological effects of warning indicators were further studied with Mendelian randomization and mediation analysis. Results: Potential risk of renal system adverse events in patients cotreated with morphine is significantly higher in FAERS (repOR 4.83, 95% CI 4.42– 5.28, false discovery rate adjusted- P =3.55&ast10 − 209 ). The analysis of in-house patient cohorts validated these results with an increased risk of acute kidney injury (adjusted OR: 1.65; 95% CI: 1.20 to 2.26), and we also found a risk of myocardial infarction in patients treated with morphine (adjusted OR: 1.55; 95% CI: 1.14 to 2.11). The Morphine group exhibited diminished Plateletcrit (PCT) levels post-surgery and lower PCT levels were associated with an increased risk of AKI. Conclusion: The administration of morphine in patients treated with P2Y12 receptor inhibitors should be carefully evaluated. PCT may serve as a potential warning indicator for morphine-related renal injury. Keywords: P2Y12 receptor inhibitors, morphine, kidney injury, Mendelian randomization Annually, an estimated 7 million individuals are diagnosed with acute coronary syndrome (ACS) globally. 1 P2Y12 receptor inhibitors are integral to ACS management, significantly reducing thrombotic events and enhancing patient prognosis. Nonetheless, the effectiveness of these agents is influenced by a variety of factors, such as patient-specific attributes and concurrent drug use. 2,3 Morphine, commonly administered for pain relief in ACS cases, has come under scrutiny for its potential to impede the absorption of P2Y12 inhibitors, thereby weakening their antiplatelet effect. Evidence from clinical randomized controlled trials indicates that morphine coadministration may lead to increased platelet reactivity when used alongside P2Y12 inhibitors. 4,5 In response to these concerns, the US Food and Drug Administration (FDA) revised the labeling for certain P2Y12 inhibitors in 2018 to include cautions regarding opioid interactions. Given that morphine is coadministered with P2Y12 inhibitors in approximately 10% to 30% of ACS patients, understanding the real-world implications of this drug interaction is critical. 6,7 However, there are few clinical studies about this interaction, and their findings are conflicting. Moreover, previous studies focused only on cardiovascular and death outcomes, the effect of this interaction on other organs is unclear. The aim of this study is to comprehensively understand the impact of the interaction between morphine and P2Y12 receptor inhibitors using various analytical methods applied to multiple data sources. Initially, signal mining was conducted utilizing data from the Food and Drug Adm -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal